• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Greatbatch wins $37.5m patent infringement suit with AVX

Greatbatch wins $37.5m patent infringement suit with AVX

January 27, 2016 By Fink Densford

Greatbatch, AVXGreatbatch (NYSE:GB) said yesterday it won $37.5 million in damages after a jury in the U.S. District Court for the District of Delaware ruled in its favor during a patent infringement case between Greatbatch and AVX.

Greatbatch filed the patent infringement complaint in April 2013, alleging that AVX infringed on patents related to filtered feedthrough assemblies used in implantable pacemakers and cardioverter defibrillators.

“Greatbatch is committed to challenging willful and deliberate patent infringement and to taking all steps necessary to ensure that our intellectual property is protected. I want to express my sincere appreciation for the time and careful attention the court and the jury gave this important case,” Greatbatch CEO Thomas Hook said in a press release.

With the ruling, the jury upheld the validity of 2 asserted patents, and 2 additional patents that AVX had challenge, Greatbatch said.

In response, AVX said it is reviewing the verdict and “consulting with its legal advisors on what action AVX may take in response,” according to a press release posted today.

Earlier this month, the Patent Trial and Appeal Board said it instituted an inter partes review of a pacemaker patent from Greatbatch, siding with challenger AVX corp that its initial decision overlooked a key argument.

AVX was granted a request for a rehearing from the same 3-judge panel that denied it last August.

The panel stated that the 1st decision was erroneous and that in consideration of the request and expert testimony, it overlooked AVX’s argument for why Greatbatch’s patent is obvious and anticipated.

The board’s rehearing determined that 10 of AVX’s multiple claims would be reviewed and were likely invalid. The board was divided on the case, with dissenting judge Elizabeth Roesel  saying that “the majority errs by relying upon argument and evidence that are not presented in the petition.”

The patent undergoing AIA review, number 7,327,553, is 1 of 5 being examined in a trial between the companies that began Monday in Delaware.

AVX challenged a separate Greatbatch patent in December, but the board ruled that all AVX’s claims were invalid.

Filed Under: Business/Financial News, Cardiac Implants, Cardiovascular, Legal News, Patent Infringement, Structural Heart Tagged With: AVX Corp, integer

More recent news

  • Medtronic escapes $106.5M payment in Colibri TAVR patent suit after court overturns jury verdict
  • RadNet closes iCAD acquisition, expands AI breast‑imaging portfolio
  • Hyperfine reports first commercial sales of next-gen AI-powered Swoop
  • Stereotaxis announces $12.5M offering
  • Nuwellis ends clinical trial of its ultrafiltration tech for heart failure

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy